KBLB Kraig Biocraft Laboratories Inc.

Kraig Biocraft Laboratories Achieves Breakthrough In Recombinant Spider Silk Design Complexity

Kraig Biocraft Laboratories Achieves Breakthrough In Recombinant Spider Silk Design Complexity

Paving the Way for Advanced Material Performance

ANN ARBOR, Mich., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), a leading developer of spider silk-based fibers, today announced a significant breakthrough in its genetic research program. The Company's research team has successfully doubled the complexity and size of its spider silk gene insert package; a milestone expected to drive new advancements in material performance.

Building on its pioneering work in recombinant spider silk production, the Company’s latest achievement represents a major step forward in the development of next-generation fibers. By expanding the gene insert package, Kraig Labs aims to create more advanced silk materials with improved strength, elasticity, and durability—critical attributes for high-performance applications in technical textiles, defense, and medical industries.

"We believe that larger and more complex gene insert packages hold the potential to unlock superior material characteristics in our spider silk fibers," said Kim Thompson, CEO and Founder of Kraig Labs. "This breakthrough reinforces our leadership in biomaterials innovation and sets the stage for the next evolution of spider silk technology."

While this cutting-edge research progresses in the lab, Kraig Labs remains committed to bringing its revolutionary spider silk fibers to market. The Company's production team continues its focus on commercial-scale spider silk manufacturing, with targeted material sales into multiple markets. Kraig Labs expects this will be a pivotal year for industry integration of spider silk.

"Our production team is on track to deliver commercial quantities of our spider silk this year, even as our research team pushes the boundaries of what's possible in the lab," added the Company’s COO, Jon Rice. "We are strategically balancing innovation and production to meet the growing demand for our game-changing materials."

With its dual focus on both research and commercialization, Kraig Labs is solidifying its position as a global leader in spider silk technology. The Company remains dedicated to transforming the future of performance materials with bioengineered spider silk.

For details about other recent Kraig Labs advancements, please watch the Company's investor conference at or on the Company's YouTube Channel .

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to .  

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

Photos accompanying this announcement are available at:



EN
26/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kraig Biocraft Laboratories Inc.

 PRESS RELEASE

Kraig Biocraft Laboratories Issues a Letter to Shareholders on Recent ...

Kraig Biocraft Laboratories Issues a Letter to Shareholders on Recent Advancements and Potential Recombinant Spider Silk Deliveries in 2025 ANN ARBOR, Mich., June 03, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, issues a letter to shareholders. Dear Shareholders, We recently received inquiries from several of our shareholders. In preparing those responses, we realized that we should share the contents with the broader Kraig Labs community. Many had questions related to last week's annou...

 PRESS RELEASE

Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain ...

Kraig Biocraft Laboratories Announces New Spider Silk Parental Strain for Expanded Commercial Production Company Expands Capacity to Meet Material Demand and Scale Inventory by developing new parental Strain for Production ANN ARBOR, Mich., May 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces today the successful development of a new recombinant spider silk parental line, purpose-built for large-scale commercial production. This newly developed strain represents the third com...

 PRESS RELEASE

Kraig Biocraft Laboratories Receives Business License to Begin Operati...

Kraig Biocraft Laboratories Receives Business License to Begin Operations in Cambodia New Location to Support Unprecedented 2025 Spider Silk Production Expansion ANN ARBOR, Mich., May 15, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces today that it has officially received its business license to begin operations in the Kingdom of Cambodia. This milestone marks a significant step in the Company’s ongoing strategy to scale up and diversify its production capabilities in response to ...

 PRESS RELEASE

Kraig Biocraft Laboratories Successfully Completes March/April Product...

Kraig Biocraft Laboratories Successfully Completes March/April Production Cycle; May Production Now Underway Company Continues to Meet 2025 Scale-Up Targets ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it has successfully completed its March/April spider silk production run and is currently well underway with its May production cycle. This steady progress reflects the Company's continued execution against its 2025 production scale-up plan,...

 PRESS RELEASE

Kraig Biocraft Laboratories Provides Production Update on Recombinant ...

Kraig Biocraft Laboratories Provides Production Update on Recombinant Spider Silk Operations ANN ARBOR, Mich., April 21, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), a world leader in spider silk technology*, is pleased to provide an update on recombinant spider silk production. The Company continues to increase its production output and is now in the middle of its largest-ever batch of recombinant spider silk production. Kraig Labs can now report that it has successfully completed the first half of its current production batch...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch